Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 167 clinical trials
featured
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

an orally-available small molecule inhibitor of KRAS G12C.

solid tumor
advanced solid tumor
malignant solid tumor
  • 405 views
  • 08 Mar, 2021
  • 67 locations
featured
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

  • 356 views
  • 08 Nov, 2020
  • 2 locations
featured
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which …

myelodysplastic syndrome (mds)
aplastic anemia
anemia
myelodysplastic syndromes
anemia studies
  • 123 views
  • 22 Dec, 2020
  • 1 location
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

, distributes and gets rid of the study dug. BAY2416964 is a small molecule which blocks the Aryl Hydrocarbon Receptor (a protein involved in immune cell reaction to tumor cells) allowing the body to use its

  • 2 views
  • 16 Apr, 2021
  • 20 locations
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid

adalimumab
immunosuppressive agents
prednisone
tumor necrosis factor
small molecule
  • 103 views
  • 24 Jan, 2021
  • 27 locations
Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib

Anlotinib is a novel small molecule multi-target tyrosine kinase inhibitor that can inhibit tumor angiogenesis and inhibit tumor cell growth. We performed second-generation gene sequencing on

tumor progression
measurable disease
karnofsky performance status
glioblastoma multiforme
neutrophil count
  • 0 views
  • 23 Jan, 2021
  • 1 location
Hydroxychloroquine and Gefitinib to Treat Lung Cancer

as ZD1839) and erlotinib (Tarceva ®, formerly known as OSI-774). Both are small molecule orally-bioavailable tyrosine kinase inhibitors (TKIs) of the EGFR TK domain, and have been shown to

growth factor
tyrosine
measurable disease
erlotinib
epidermal growth factor
  • 39 views
  • 07 Nov, 2020
  • 1 location
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3

hysterectomy
measurable disease
serum pregnancy test
pd-l1
platinum-based chemotherapy
  • 46 views
  • 26 Jan, 2021
  • 12 locations
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

APG-1387 is a potent, bivalent small-molecule Inhibitor of Apoptosis Protein (IAP) antagonist. APG-1387 has shown strong dose- and schedule-dependent antitumor activities in multiple human

  • 11 views
  • 28 Jan, 2021
  • 3 locations
Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients

(biologic or small molecule) has advanced to clinical trials. Tyzivumab will be the first therapeutic in the world, specifically targeting ZIKV, to enter clinical trials. This is a Phase 1, time

  • 4 views
  • 23 Jan, 2021
  • 1 location